Edwards B E, Gearhart J D, Wallach E E
Department of Gynecology and Obstetrics, The Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA.
Fertil Steril. 2000 Jul;74(1):1-7. doi: 10.1016/s0015-0282(00)00583-5.
To discuss the current state of the science surrounding human pluripotent stem cells and to show that the derivation of such cells from donated preimplantation human embryos should be eligible for federal funding provided that certain protections are met.
A literature search focusing on the scientific aspects of pluripotent stem-cell research and analyses of current and past legislation and federal panel recommendations.
CONCLUSION(S): The current federal laws regulating the permission necessary to obtain fetal tissue from elective pregnancy terminations are intended to insulate the decision to terminate a pregnancy from the potential positive influence of fetal tissue transplantation. A similar situation can be created for the derivation of cells from excess preimplantation human embryos produced by IVF programs. If, as in fetal tissue research, assurances can be made that the research will have no influence on the decision to dispose of the embryo, the derivation of pluripotent stem cells from embryo should proceed with federal funding.
探讨围绕人类多能干细胞的科学现状,并表明在满足某些保护条件的情况下,从捐赠的植入前人类胚胎中获取此类细胞应符合获得联邦资金资助的条件。
一项聚焦于多能干细胞研究科学方面的文献检索,以及对现行和过往立法及联邦小组建议的分析。
当前关于从选择性终止妊娠获取胎儿组织所需许可的联邦法律,旨在使终止妊娠的决定免受胎儿组织移植潜在积极影响。对于从体外受精项目产生的多余植入前人类胚胎中获取细胞,也可营造类似情形。如果像在胎儿组织研究中那样,能够保证该研究不会对处置胚胎的决定产生影响,那么利用联邦资金从胚胎中获取多能干细胞的工作就应继续进行。